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Preparations  of mycobacteria have  been  used  as  adjuvants  for many years.  The 
glycopeptide muramyl dipeptide, N-acetylmuramyl-k-alanyl-D-isoglutamine (MDP),t 
which  was  synthesized  to  correspond  to  a  component  of mycobacterial  cell  wall, 
represents  the  minimal  chemical  structure  required  for  the  adjuvant  activity  of 
complete Freund's adjuvant (1, 2). The adjuvanticity of MDP in the primary antibody 
response has been attributed to stimulation of either T  or B lymphocytes, or both, or 
to stimulation of macrophages, resulting in increased antigen processing or increased 
lymphocyte stimulation  by  monokines  (3). When  added  to  cultured  cells  in  vitro, 
MDP  also  stimulates  a  variety  of macrophage  functions  that  are  not  necessarily 
related to the response to specific antigens, namely, inhibition of macrophage migra- 
tion  (4),  release  of endogenous  pyrogen  (5),  production  of lymphocyte-activating 
factor  (6),  enhanced  production  of collagenase  and  prostaglandins  (7),  increased 
uptake  of  glucosamine  (8),  inhibition  of  growth  of  mastocytoma  cells  (9),  and 
augmented direct cytolytic activity against tumor target cells  (10).  We have recently 
shown that  the addition of MDP to mouse peritoneal  macrophages in  vitro primed 
these cells to produce increased amounts of superoxide anion (OF)  during stimulation 
by phorbol  myristate  acetate  (PMA)  or phagocytosis of opsonized zymosan. MDP 
appeared to affect the macrophages directly, without a  requirement  for lymphocyte 
involvement  (1 1).  This  enhanced  ability  to  secrete  microbicidal  and  tumoricidal 
oxygen metabolites appears to be a fundamental component of macrophage activation 
(12,  13). 
We have extended  these in vitro observations by studying the effects of MDP on 
macrophages in the intact animal. We report here that subcutaneous administration 
of MDP  to mice induces in  their  peritoneal  macrophages, morphologic, metabolic, 
and  microbicidal  properties  of "activated"  macrophages.  Injection  of MDP  also 
prepares  the  mice  to  withstand  more  effectively  a  lethal  infectious  challenge  by 
Candida  albicans. 
* Supported by grants AI 14148 and DE 05494 from the National Institutes of Health. 
i Abbreviations used in this paper: BCG, bacillus Calmette-Gu~rin; FCS, fetal calf serum; HBSS, ttanks' 
balanced salt solution; LDH, lactate dehydrogenase; LPS, lipopolysaccharide: MDP, N-acetylmuramyl- 
L-alanyl-o-isoglutamine; 02, superoxide anion: PMA, phorbol myristate acetate. 
J. ExP. M  ED. © The Rockefeller University Press • 0022-1007/80/12/1659/11 $1.00  1659 
Volume 152  December  1980  1659-1669 1660  MACROPHAGE ACTIVATION BY  MURAMYL  DIPEPTIDE 
Materials and Methods 
Macrophage Cultures.  Peritoneal  leukocytes were harvested  from 4- to 8-wk-old Swiss-Web- 
ster mice (13).  Nude mice were purchased from Taconic Farms, Germantown, N. Y. Cells were 
washed and allowed to adhere for 2 h to tissue culture dishes in medium containing penicillin, 
streptomycin,  and  20%  heat-inactivated  (56°C  for  30  min)  fetal  calf serum  (FCS;  Sterile 
Systems,  Logan,  Utah),  as  previously described  (13).  Adherent  cells were washed  vigorously 
twice  with  Hanks'  balanced  salt  solution  (HBSS;  Microbiological  Associates,  Walkersville, 
Md.).  After the  initial  2-h  adherence,  cells were assayed  or incubated  overnight  in  medium 
with 20% FCS and antibiotics. All solutions were free from bacterial lipopolysaceharide (LPS), 
as tested by the limulus amebocyte lysate assay (E-toxate; Sigma Chemical Co., St. Louis, Mo.), 
except that  FCS contained  125  pg/ml LPS.  Therefore, medium  with  20%  FCS contained  25 
pg/ml of LPS, which is less than the minimum concentration of LPS (100 pg/ml) that we have 
found capable of detectably affecting macrophages overnight in vitro (11)~ Cells adherent after 
2 h were >97% macrophages, as determined by examination of stained cells and by phagocytosis 
of Candida (14); after overnight culture, <1% of adherent  cells were polymorphonuclear. 
Determination of Cell Number.  Cells adherent  to culture dishes were Iysed with Zap-Ogtobin 
II (Coulter Diagnostics, Inc., Hialeah, Fla.). The residue was scraped off the dish with a rubber 
policeman, diluted  1:20 in HBSS, and nuclei were counted with a  Coulter counter Model ZB 
(Coulter  Diagnostics,  Inc.).  In  early experiments,  nuclei counts  were confirmed  by counting 
with a  hemocytometer. 
O~ Release.  Adherent cells were washed  twice with HBSS, then assayed  for production  of 
O~-  measured  as  superoxide  dismutase-inhibitable  reduction  of ferricytochrome c  (13).  The 
stimulus was PMA (Consolidated  Midland Corp., Brewster, N. Y.), 0.5/lg/ml. After removal 
of the  O~  assay  mixture,  the  cells  were  washed  three  times  with  HBSS;  and  protein  was 
determined by the Lowry method (11).  In some experiments, three to five separate dishes were 
assayed  for protein  after washing but  without  addition  of the O~-  reaction  mixture;  protein 
contents were equivalent with the two procedures. 
Enzyme Assays.  N-acetyl-/~-glucosaminidase was assayed by a modification of the method of 
Woolen et al. (15).  Results are expressed as nanomoles ofsubstrate hydrolyzed in 1 min. Lactate 
dehydrogenase  (LDH)  was assayed  by determining  the rate of oxidation of reduced  nicotin- 
amide-adenine dinucleotide (Sigma Chemical Co.) at 340 nm (15).  The amount of LDH that 
was  released  into  the culture  supernate  was  expressed  as  the  percentage  of total  cell  LDH, 
determined by lysis of the cultures with 0.05% Triton X-100.  I U  of LDH activity was defined 
as a  decrease in optical density of 0.001/min. 
Phagocytosis of Candida.  C. albicans (ATCC 18804)  was used for phagocytosis and phagocytic 
killing assays,  as  previously described  (14).  Candida (1  ×  106 in 0.5  ml HBSS with  20%  fresh 
FCS) were added to ~3 ×  10  s washed cells adherent after overnight culture to 13-mm-diameter 
cover slips. After incubation, cover slips were washed,  then double-stained with Wright's and 
Giemsa stains. Approximately 95% of cell-associated Candida could be seen within a  detectable 
phagocytic vacuole (14).  Slides were coded and read without knowledge of macrophage origin. 
The  percentage  of 200  macrophages  that  ingested  one or more  Candida, and  the  number  of 
Candida/200 macrophages,  were determined. 
Phagocytosis was also studied using Candida labeled with fluorescein isothiocyanate  (Calbi- 
ochem  Behring  Corp.,  American  Hoechst  Corp.,  San  Diego,  Cal.)  (16),  as  described  (14). 
Crystal violet, 0.5 mg/ml, abolished fluorescence of extracellular but not intracellular Candida, 
allowing the differentiation of ingested from attached fungi. In three comparative experiments, 
results at 60 min with this technique were identical to those obtained with stained cells (above)~ 
CandidacidalAssay.  Peritoneal cells were plated on 16-mm-diameter dishes to yield equivalent 
numbers of adherent  macrophages after overnight culture, regardless of the source of the cells, 
based on counts of macrophage nuclei in separate dishes and on counting cells in representative 
fields of the dishes to be used in the assay (14).  Macrophages were washed, then incubated with 
105 Candida in 0.5 ml HBSS with 20% fresh FCS at 37°C in 5% CO2-95% air~ The macrophage: 
Candida ratio was -3:1. The reaction was stopped by sonication for 30 s, and diluted suspensions 
were cultured in pour plates made with Sabouraud's agar (14).  The number of colonies formed 
was determined in plates from triplicate reaction mixtures. 
Protection against Death by Candida Infection.  C. albicans isolated  from  the blood of a  patient N.  P.  CUMMINGS, M. J.  PABST,  AND  R.  B. JOHNSTON, JR.  1661 
with disseminated candidiasis was grown in Sabouraud's broth for 18 h  at 37°C. Candida  were 
washed  twice with  HBSS  and  counted  with  a  hemocytometer. Each  animal  was  given  an 
injection of 2 ×  106 fungi into the lateral tail vein. 
Injection  of MDP.  MDP  and  the  D-D  stereoisomer of MDP,  obtained  from  Calbiochem- 
Behring Corp., were diluted in nonpyrogenic saline to a concentration of 500 #g/ml. Injections 
were made into the flank using a  No.  26  needle. In  most experiments, saline was injected as 
control. However, values with cells from saline controls were no different than those obtained 
with cells from animals given the D-D stereoisomer (as noted) or no injection. This preparation 
of MDP, a  second MDP preparation generously given us by Dr.  S.  Kotani, Osaka University, 
Japan, and a  third preparation purchased from the Pasteur Institute, Paris, when incubated in 
vitro with resident macrophages, primed them to an almost identical extent to release increased 
amounts of O~- when stimulated with PMA (11).  All MDP solutions were negative for LPS by 
the limulus assay (11). 
The MDP obtained from Calbiochem-Behring Corp., at concentrations of 5 and 30 p,g/ml, 
did not activate the alternative pathway during incubation for  15 or 30 rain in either pooled 
human serum or serum from Swiss-Webster mice, using a sensitive kinetic hemolytic assay (17). 
Phenol-extracted LPS  (11),  30 p,g/ml, vigorously activated  the alternative pathway  in  both 
types of sera.  MDP,  5  and  30/~g/ml,  also did not  activate the classical  pathway in  human 
serum when incubated at  37°C  for 30  min, using antibody-coated sheep erythrocytes in  the 
same kinetic system. 
Results 
Macrophage Spreading, Protein Content, and Enzyme Activities.  Table I summarizes the 
effects of injection of MDP on certain properties of peritoneal macrophages that have 
been  associated previously with  macrophage activation  (13,  18-20).  Macrophages 
from  MDP-treated  mice  showed  enhanced  spreading  during  2  h  of adherence, 
increased  protein  content,  greater  total cell  activity of the  lysosomal hydrolase fl- 
glucosaminidase, and  increased  total  cell  activity of LDH.  fl-glucosaminidase re- 
TABLE  I 
Effect of lnjection  of Mice with MDP on Peritoneal Macrophages * 
Macrophage function or con- 
stituent 
Pretreatment of mice:~ 
Saline  MDP 
Spreading (% of cells elongated)§  3.6 + 0.7  11.8 +  1.2 (33) 
Protein content (/.tg/lO  6 adherent  93 _-- 19  134 --- 36 (7) 
cells) 
fi-glucosaminidase activity (nmol/  116 ±  16  173 ±  12 (7) 
min per mg protein) 
Lactate dehydrogenase activity  1,143 +  181  1,791 ::t  130 (3) 
(U/mg protein) 
* Mice were injected subcutaneously with 25-1130 #g MDP or saline  ~ 18  h  before 
collecting cells  from  the  peritoneal cavity.  After incubation  on  dishes  for  2  h, 
nonadherent  cells  were  washed  away,  and  the  adherent  cells  were  studied  as 
described. Cells studied for fi-glucosaminidase  and LDH activities  were from mice 
given  100 #g MDP. 
:~ Mean ±  SEM. Number of paired experiments is given in parentheses in the MDP 
column. Each experiment was  performed with cells pooled from  2-10 mice,  and 
tested in duplicate or triplicate. Results were significantly  greater with cells from 
MDP-treated mice (P <  0.01 for protein content, P  <  0.001 for the other three 
variables,  paired t test). 
§ Elongated cells had a  length:width ratio of >1.5,  as detected with phase-contrast 
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mained significantly higher in cells from MDP-treated mice after 24 or 48 h in culture 
(five expei, iments). Release of LDH, an indicator of cell death, was equivalent in the 
two cell populations after culture for 24 and 48 h  (n -- 5).  Treatment  of mice with 
MDP also increased the number of peritoneal cells  obtained -18 h  later  (3.6  -+ 0.3 
and  5.7  ±  0.2  X  106 cells/mouse  for control  and  MDP-treated  mice,  respectively; 
mean  ±  SEM  for six  pools of cells).  The percentage of these cells  that  adhered  to 
culture dishes as macrophages was equivalent in the two groups of mice (-30%, n = 
7). 
In  view of the  possible  relationship  of macrophage stimulation  by  MDP  to  the 
adjuvanticity of this compound (3),  additional  experiments  were performed testing 
the  effects  of injection  of the  D-D  stereoisomer  of MDP,  which  is  inactive  as  an 
adjuvant.  In two paired  experiments,  results  with  macrophages pooled from six  to 
eight  mice given D-D MDP were almost identical to those with macrophages from 
saline-injected animals for each of the four variables of Table I and for the number 
of peritoneal cells  obtained per mouse.  Results with cells  from animals given saline 
were equivalent in these experiments and the paired experiments of Table I. 
Generation of 0~.  Macrophages  obtained  from  inflammatory  exudates  or  from 
BCG-infected mice,  or  macrophages incubated  with  MDP  in  vitro,  are  primed  to 
release greater amounts of O~- when stimulated with PMA than are resident cells  (11, 
13). MDP, 25-100 ~g administered subcutaneously 18 h before macrophage harvest- 
ing, primed peritoneal macrophages to produce up to five times moreO~- than control 
macrophages produced (Fig.  1). A dose of 50 ~g MDP was employed to evaluate the 
time  course of the O~-  effect  (Fig.  2).  Some enhancement  in  PMA-stimulated O~- 
release  was  noted  1 h  after  injection.  The enhanced O~-  response  reached optimal 
levels by 3 h  after MDP injection and remained at such levels  for at least 48 h. 
The  results  shown in  Figs.  1 and  2 were obtained  with  macrophages allowed  to 
adhere for 2 h; in six experiments with mice given 50 ~g MDP 18 h before macrophage 
harvest, the release of O~- from macrophages cultured overnight was almost identical 
to release from macrophages stimulated after 2-h adherence (645  ±  67 and 651  +  49 
nmol/mg,  respectively).  Injection of the  D-D stereoisomer of MDP  did  not  prime 
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FIG.  1.  Effect of pretreatment of mice with varying amounts of MDP on the release of  O~-  by 
cultured peritoneal macrophages  stimulated by 0.5/~g/ml PMA. The mean ± SEM of three to five 
experiments  is  shown at  each amount given; each of these experiments was  performed with 
peritoneal cells pooled from four to six mice, and placed into triplicate dishes. N.  P.  CUMMINGS,  M.  J.  PABST, AND R.  B. JOHNSTON,  JR. 
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Fic.  2.  The extent of PMA-stimulated 02  release by cultured peritoneal macrophages plotted as 
a  function of the time at which macrophages were harvested after injection of 50/.tg  of MDP. The 
mean 4" SEM of four to six experiments is shown at each time point. 
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Fie. 3.  Extent of 0~  release by peritoneal macrophages from nude mice (nu/nu)  and normal 
littermates on a Swiss-Webster background (nu/S/W) treated with MDP  18 h prior to macrophage 
harvesting. The means of triplicate  values are shown for one representative experiment of three 
performed with varying amounts of MDP. In each, the response to injection of MDP was equivalent 
in nude mice and littermates, and two- to fivefold  greater than the PMA-stimu[atedO~ response of 
control mice. 
peritoneal  macrophages for enhanced O~-  response  (165  ±  20  nmol/mg,  compared 
with  148 ±  12 nmol/mg for control cells; n -- 2). 
We explored the question of whether MDP might act directly on the macrophage 
or whether it interacts with lymphocytes to cause production of lymphokines, which 
would,  in  turn,  activate  the  macrophages.  Nude  mice  (nu/nu,  on  Swiss-Webster 
background),  which  lack  mature  T  cells,  were  pretreated  with  MDP  in  varying 
amounts. Normal littermates (nu/S/W)  were used as controls. Fig. 3 shows that both 
nu/nu  mice and littermates responded in a similar fashion to MDP, suggesting that 
mature T-cell  function  is  not  essential  for the  MDP-mediated  enhancement  of O~ 
release. 
Phagocytosis and  Killing  of Candida.  The  capacity  of  control  and  MDP-treated 
macrophages to ingest Candida was compared. As noted in Fig. 4 A, at all time points 
a slightly higher percentage of macrophages from MDP-treated mice were phagocytic, 
and MDP macrophages ingested slightly more Candida (Fig. 4 B). 
The killing of (2. albicans by adherent macrophages is demonstrated in Fig. 5. Studies 
were performed at a  ratio of ~ 1 Candida:3 macrophages in the presence of 20% fresh 1664  MACROPHAGE  ACTIVATION  BY  MURAMYL  DIPEPTIDE 
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FIc.  4.  Phagocytosis of C. albicans by cultured macrophages from control mice and mice given 50 
~g MDP 18 h previously.  The candida:macrophage ratio was ~3:1. The percentage of macrophages 
ingesting at least one organism (A), and the number of candida ingested by 100 macrophages (B) 
are plotted. The mean +  SEM of six experiments are shown. The difference in phagocytosis shown 
in panel A is significant at the level of P <  0.01  (analysis of variance, repeated measures)  and in 
panel B at the level of P <  0.05. 
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l-'lc.  5.  The killing of C. albicans by macrophages from control or MDP-treated mice. Means + 
SEM of six matched experiments are shown. Control cells killed 10.6 ±  2.3% of the fungi after 3 h; 
macrophages from mice given 50 p.g MDP killed 21.5 ±  1.5'7~. 
FCS.  Under  these conditions, >99%  of Candida  on stained cover slips were ingested by 
60  rain.  Crystal  violet  did  not  extinguish  the  fluorescence  of  fluorescein-labelled 
Candida,  confirming  the  ingestion  of all  Candida  by  60  rain.  Candida  were  not  easily 
killed by the macrophages,  in agreement  with the killing of only  15-36% of C. albicans 
by human  monocytes  and  neutrophils  (21)  and  rabbit  peritoneal  macrophages  (22). 
However, macrophages  from MDP-treated  mice killed approximately  two times more 
Candida  than  did  control  cells  at  each  time  point  studied,  and  this  difference  was 
significant  at  each  time point  (P <  0.001,  t  test). The  killing of Candida  by cells from N.  P. CUMMINGS,  M. J.  PABST, AND  R.  B. JOHNSTON,  JR.  1665 
mice given  the  D-D  stereoisomer  (I0.0  +  0.2%)  was equivalent  to killing with cells 
from control mice (12.9  +  0.3%,  mean ±  SEM, n =  2 at  1 h). 
Protection of Mice against Candida Challenge.  5- to 6-wk-old mice were given 50/~g of 
MDP  subcutaneously  either  18  h  before,  immediately  after,  or  24  h  after  being 
infected  intravenously with 2  ×  106 C. albicans. Mortality  was recorded  for  16  d.  As 
shown  in  Fig.  6A,  MDP  given  to  10  mice  18  h  before  challenge  resulted  in  60% 
survival of the mice by day 7, by which time all  10 control mice had died. In a second 
experiment  with  15  7-wk-old mice  (data not plotted),  injection of 50 #g  MDP  18  h 
before infection permitted 50% survival by day  12, by which time all  15 control mice 
had died.  In Fig.  6B, similar results were obtained when injection of MDP  immedi- 
ately  followed  infectious  challenge  in  12  mice,  survival  being  58%  by  day  7.  Even 
when MDP was given 24 h after the Candida challenge (15 mice), some protection was 
still observed in MDP-treated  mice as compared with control mice (Fig. 6 C). 
Discussion 
The designation "activated" was originally applied to macrophages obtained from 
animals that had enhanced ability to resist infection (19). Biochemical, morphologic, 
and functional characteristics of macrophages from such animals have been described 
subsequently  (12,  13,  18,  19).  By  several  of these  criteria,  we  have  demonstrated 
activation  of  mouse  peritoneal  macrophages  after  subcutaneous  injection  of  the 
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Fie.  6.  Effect  of survival from infection with C. albicans of mice treated with  MDP.  (A)  MDP,  50 
/~g, was administered subcutaneously to  10 mice 18 h before administration ofcandida intravenously. 
(B)  MDP,  50 #g, was administered  to  12 mice within  1 min after candida challenge.  (C)  MDP,  50 
~g, was administered  to  15  mice  24 h  after candida  challenge.  In each experiment  the  number of 
control  mice (no MDP)  was identical  to or greater than the number receiving MDP. 1666  MACROPHAGE ACTIVATION BY MURAMYL DIPEPTIDE 
adjuvant  MDP:  Mice treated  with  MDP  showed  increased  numbers  of peritoneal 
macrophages,  and  when  cultured,  these macrophages  showed more spreading and 
increased  total  cell  protein.  Total  cellular  content  of the  lysosomal  hydrolase fl- 
glucosaminidase and of the cytoplasmic enzyme LDH was  increased, as previously 
reported  with  macrophages  elicited  by  thioglycoilate,  streptococcal  protein  A,  or 
protease-peptone (20). Enhancement of the phagocytosis-associated burst of oxidative 
metabolism  also  appears  to be a  manifestation of macrophage activation  (12,  13). 
Macrophages  obtained from animals  infected with  BCG have been shown  to have 
increased potential for generating O~  (13) and hydrogen peroxide (12)  when stimu- 
lated  by  phagocytosis or contact  with  PMA.  A  similar  priming  for enhanced O~- 
generation was achieved by incubating MDP with mouse peritoneal macrophages in 
vitro (11). In the present report, we have shown that MDP given in vivo also markedly 
enhanced  PMA-stimulated O~-  release. The absolute  levels of O~-  release achieved 
were equivalent to those obtained previously with macrophages from animals infected 
with BCG (13). 
MDP treatment enhanced phagocytosis of C. albicans only slightly. Previous studies 
have shown  that  the  rate  of clearance of carbon  particles  from  the  blood stream, 
presumably a phagocytosis-dependent event, was enhanced in MDP-treated mice (23, 
24). 
The enhanced microbicidal potential of macrophages from MDP-treated animals 
was  confirmed  by  direct  testing.  Macrophages  from  mice  pretreated  with  MDP 
consistently killed over two times  more  C.  albicans than  did  resident  macrophages. 
This doubling of candidacidal activity is almost identical to that observed with LPS- 
elicited or BCG-activated mouse peritoneal macrophages (14) and Freund's adjuvant- 
elicited rabbit  peritoneal  macrophages  (22). The extent  of killing of C.  albicans by 
mouse  macrophages  is  equivalent  to  that  reported  with  human  neutrophils  or 
monocytes (21). 
The molecular basis  for the enhanced killing capacity of MDP-activated macro- 
phages  has  not  been  completely defined.  It  is  unlikely  that  the  slightly  increased 
phagocytosis  by  MDP  macrophages  played  an  important  part;  moreover,  in  the 
candidacidal  system,  all  candida  were  ingested  after  60  min  by  both  types  of 
macrophages. We have previously reported data to suggest that the enhanced candi- 
dacidal  capacity of BCG-activated and  LPS-elicited macrophages  is  dependent  on 
their increased oxidative metabolic response (14), and it seems highly likely that the 
enhanced candidacidal activity of macrophages from MDP-treated animals results at 
least in part from this enhancement. Others have reported a similar association with 
the enhanced killing of Toxoplasma gondii (25, 26) and  Trypanosoma cruzi (27). A higher 
content  in  MDP  macrophages of hydrolytic enzymes, as represented  by fl-glucosa- 
minidase, could also be relevant. 
The enhanced phagocytic killing ability of macrophages from MDP-treated mice 
presumably played an important rote in protecting the mice against lethality from C. 
albicans infection, although other immunostimulatory effects of MDP also could have 
been involved. MDP and certain MDP analogs have been reported to protect both 
adult  and neonatal mice challenged with lethal Klebsiella infection (24, 28)  or adult 
mice infected with T. cruzi (29). Direct injection into tumors of certain MDP analogs, 
along with trehalose dimycolate, has been associated with tumor regression in guinea N.  P. CUMMINGS, M. J.  PABST, AND R. B. JOHNSTON, JR.  1667 
pigs  (30).  In  contrast,  100-500 /~g of MDP  given  intraperitoneaUy 20  min  or 5  d 
before infection did not protect against lethal challenge by Listeria monocytogenes (31). 
The mechanism for the rapid, apparently T-cell-independent activation of perito- 
neal  macrophages  by MDP  injected at  a  distant  site  is not  known.  MDP  did  not 
activate  complement  in  vitro  by  either  the  classical  or  alternative  pathways,  but 
stimulation of the formation or release of other humoral factors or interaction with 
complement components on the surface of the macrophage is possible. It is clear that 
MDP can induce functional changes in adherent macrophages when added to these 
cells in vitro (4, 5, 8-11), and vigorous efforts to exclude iymphocytes as mediators of 
these effects (4,  1 l)  have indicated that  MDP can act  directly on the macrophage. 
Moreover, some of these changes are induced within a  few hours after contact with 
MDP  (4,  11),  which  is  more  prompt  than  would  be  expected  for a  lymphokine- 
dependent effect (27).  Thus, extrapolation from  these in  vitro data  favors a  direct 
effect of injected MDP on the macrophage. 
The  experiments  reported  here  show  clearly  that  injection  of MDP  activates 
macrophages  by  morphologic,  metabolic,  and  microbicidal  criteria.  These  results 
indicate that  MDP  has important  potential as a  tool for the study of macrophage 
physiology. Our studies also indicate that MDP offers promise as a means of  enhancing 
host  defense. The adverse side effects of BCG and  larger cell wall extracts, such as 
granuloma  formation and  adjuvant  polyarthritis  (3,  32),  and  the  potential danger 
from administering a  viable organism like BCG, are lacking when MDP is given in 
saline. In fact, the only deleterious effect thus far reported with MDP has been mild 
pyrogenicity in rabbits (5). The apparently direct effect of MDP on the macrophage, 
bypassing  the  T  lymphocyte, suggests  particular  usefulness  of this  compound  for 
treating the immunocompromised host. 
Summary 
The adjuvant  muramyl dipeptide  (MDP)  has been shown  to affect a  number of 
macrophage  functions  in  vitro.  We studied  the effect of subcutaneous  injection of 
MDP  into  mice.  Cultured  peritoneal  macrophages  from  treated  mice  displayed 
increased spreading,  total cell protein, and specific activity of fl-glucosaminidase, a 
constituent of macrophage lysosomes, and  of lactate dehydrogenase. Generation of 
superoxide  anion  (02)  by  MDP-treated  macrophages  stimulated  by contact  with 
phorbol  myristate  acetate  was  enhanced  by  over  fivefold  to  levels  achieved  by 
macrophages  from  bacillus  Calmette-Gu~rin-infected  mice.  The  enhancement  in 
stimulated 02 release was noted by  1 h after injection of MDP, peaked by 3 h, and 
remained high for at least 48 h. Priming for enhancement of  O~-  release by MDP was 
similar in athymic nude mice and  in normal littermates, suggesting that  mature T 
lymphocytes are not involved in this MDP effect. Priming for enhanced stimulated 
02 release, and morphologic and enzymic changes, were not achieved by injection of 
the  D-D  stereoisomer of MDP.  Phagocytosis of Candida albicans was  only slightly 
greater by macrophages from mice given MDP, but MDP-stimulated cells killed two 
times more C. albicans in vitro than did cells from untreated animals. When MDP was 
given  18 h  before, simultaneously with, or 24 h after lethal infectious challenge with 
C. albicans, treated mice were protected compared with controls. These results suggest 
that injection of MDP effectively and rapidly activates macrophages in the recipient 1668  MACROPHAGE  ACTIVATION BY  MURAMYL DIPEPTIDE 
animal.  This  agent  should  serve as an  important  probe of macrophage  physiology 
and, perhaps ultimately, as a  means of enhancing host defense in humans. 
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